**Supplementary Table 2. Risk of bias assessment**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Study name**  | **Random sequence generation**  | **Allocation concealment**  | **Blinding of participants and personnel**  | **Blinding of outcome assessment**  | **Incomplete outcome data**  | **Selective reporting**  | **Other bias**  |
| Acharya et al.1 | Low  | Low  | Low  | Low  | Low  | Low  | Low  |
| Avgerinos et al.2  | Low  | Low  | Low  | Low  | Low  | Low  | Low  |
| Banares et al.3 | Low  | Low  | Unclear  | Low  | Low  | Low  | Low  |
| Banares et al.4  | Low  | Low  | High  | Low  | Low  | Low  | Low  |
| Bhardwaj et al.5 | Low  | Low  | High  | High  | High  | High  | High  |
| Binay K De et al.6  | Low  | Low  | Low  | Low  | Low  | Low  | Low  |
| Bonilha et al.7 | Low  | Low  | High  | High  | Low  | Low  | Low  |
| Burroughs et al.8 | Low  | Low  | High  | High  | Low  | Low  | Low  |
| Colombo et al.9 | Low  | Low  | High  | High  | Low  | Low  | Low  |
| Conn et al.10 | Low  | Low  | Low  | Low  | Low  | Low  | Low  |
| Garden et al.11  | Low  | Low  | Low  | High  | Low  | Low  | Low  |
| Groszmann et al.12  | Low  | Low  | Low  | Low  | Low  | Low  | Low  |
| Gupta et al.13 | Low  | Low  | High  | High  | High  | Low  | Low  |
| Hobolth et al.14 | Low  | Low  | Low  | Unclear  | High  | Low  | Low  |
| Ideo et al.15 | Low  | Low  | Low  | Low  | Low  | Low  | Low  |
| The Italian multicenter project16  | Low  | Low  | High  | High  | Low  | Low  | Low  |
| Jensen et al.17 | Low  | Low  | Low  | Low  | Low  | Low  | Low  |
| Kim et al.18 | Low  | Low  | High  | High  | Low  | Low  | Low  |
| Kumar et al.19  | Low  | Low  | Low  | Low  | Low  | Low  | Low  |
| Kumar et al.20  | Low  | Low  | Low  | Low  | Low  | Low  | Low  |
| Lebrec et al.21 | Low  | Low  | Low  | Low  | High  | Low  | Low  |
| Lo et al.22 | Low  | Low  | Low  | Low  | Low  | Low  | Low  |
| Lo et al.23 | Low  | Low  | Low  | Low  | Low  | Low  | Low  |
| Lo et al.24 | Low  | Low  | Low  | Low  | Low  | Low  | Low  |
| Merkel et al.25 | Low  | Low  | High  | High  | Low  | Low  | Low  |
| Pascal et al.26 | Low  | Low  | Low  | Low  | Low  | Low  | Low  |
| Peña et al.27 | Low  | Low  | Low  | Low  | Low  | Low  | Low  |
| Perez-Ayuso et al.28 | Low  | Low  | High  | High  | Low  | Low  | Low  |
| Pomier-Layrargues et al.29 | Low  | Low  | Unclear  | Unclear  | High  | Low  | Low  |
| Sarin et al.30 | Low  | Low  | High  | High  | High  | Low  | Low  |
| The PROVA study group31  | Low  | Low  | High  | High  | Low  | Low  | Low  |
| Villanueva et al.32  | Low  | Low  | Low  | Low  | Low  | Low  | Low  |
| Villeneuve et al.33  | Low  | Low  | High  | High  | Low  | Low  | Low  |

## References

[1] Acharya SK, Dasarathy S, Saksena S, Pande JN. A prospective randomized study to evaluate propranolol in patients undergoing long-term endoscopic sclerotherapy. J Hepatol 1993;19(2):291-300. doi: 10.1016/s0168-8278(05)80585-9. PMID: 8301064

[2] Avgerinos A, Rekoumis G, Klonis C, Papadimitriou N, Gouma P, Pournaras S*, et al.* Propranolol in the prevention of recurrent upper gastrointestinal bleeding in patients with cirrhosis undergoing endoscopic sclerotherapy. A randomized controlled trial. J Hepatol 1993;19(2):301-311. doi: 10.1016/s0168-8278(05)80586-0. PMID: 8301065

[3] Bañares R, Moitinho E, Piqueras B, Casado M, García-Pagán JC, de Diego A*, et al.* Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology 1999;30(1):79-83. doi: 10.1002/hep.510300124. PMID: 10385642

[4] Bañares R, Moitinho E, Matilla A, Garcı́a-Pagán JC, Lampreave JL, Piera C*, et al.* Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology 2002;36(6):1367-1373. doi: [10.1053/jhep.2002.36947.](https://doi.org/10.1053/jhep.2002.36947.) PMID: 12447861.

[5] Bhardwaj A, Kedarisetty CK, Vashishtha C, Bhadoria AS, Jindal A, Kumar G*, et al.* Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial. Gut 2017;66(10):1838-1843. doi: 10.1136/gutjnl-2016-311735. PMID: 27298379

[6] De BK, Das D, Sen S, Biswas PK, Mandal SK, Majumdar D*, et al.* Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics. J Gastroenterol Hepatol 2002;17(2):183-189. doi: 10.1046/j.1440-1746.2002.02674.x. PMID: 11966949

[7] Bonilha DQ, Lenz L, Correia LM, Rodrigues RA, de Paulo GA, Ferrari AP*, et al.* Propranolol associated with endoscopic band ligation reduces recurrence of esophageal varices for primary prophylaxis of variceal bleeding: a randomized-controlled trial. Eur J Gastroenterol Hepatol 2015;27(1):84-90. doi: 10.1097/meg.0000000000000227. PMID: 25397691

[8] Burroughs AK, Jenkins WJ, Sherlock S, Dunk A, Walt RP, Osuafor TO*, et al.* Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. N Engl J Med 1983;309(25):1539-1542. doi: 10.1056/nejm198312223092502. PMID: 6361553

[9] Colombo M, de Franchis R, Tommasini M, Sangiovanni A, Dioguardi N. Beta-blockade prevents recurrent gastrointestinal bleeding in well-compensated patients with alcoholic cirrhosis: a multicenter randomized controlled trial. Hepatology 1989;9(3):433-438. doi: 10.1002/hep.1840090315. PMID: 2563985

[10] Conn HO, Grace ND, Bosch J, Groszmann RJ, Rodés J, Wright SC*, et al.* Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial. Hepatology 1991;13(5):902-912. doi: [10.1002/hep.1840130517.](https://doi.org/10.1002/hep.1840130517.) PMID: 2029994

[11] Garden OJ, Mills PR, Birnie GG, Murray GD, Carter DC. Propranolol in the prevention of recurrent variceal hemorrhage in cirrhotic patients. A controlled trial. Gastroenterology 1990;98(1):185-190. doi: 10.1016/0016-5085(90)91308-s. PMID: 2403428

[12] Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M*, et al.* Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990;99(5):1401-1407. doi: 10.1016/0016-5085(90)91168-6. PMID: 2210246

[13] Gupta V, Rawat R, Shalimar, Saraya A. Carvedilol versus propranolol effect on hepatic venous pressure gradient at 1 month in patients with index variceal bleed: RCT. Hepatol Int 2017;11(2):181-187. doi: 10.1007/s12072-016-9765-y. PMID: 27624505

[14] Hobolth L, Møller S, Grønbæk H, Roelsgaard K, Bendtsen F, Feldager Hansen E. Carvedilol or propranolol in portal hypertension? A randomized comparison. Scand J Gastroenterol 2012;47(4):467-474. doi: 10.3109/00365521.2012.666673. PMID: 22401315

[15] Idéo G, Bellati G, Fesce E, Grimoldi D. Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: a prospective, randomized study. Hepatology 1988;8(1):6-9. doi: 10.1002/hep.1840080103. PMID: 3276591

[16] The Italian Multicenter Project for Propranolol in Prevention of Bleeding. Propranolol for prophylaxis of bleeding in cirrhotic patients with large varices: a multicenter, randomized clinical trial. The Italian Multicenter Project for Propranolol in Prevention of Bleeding. Hepatology 1988;8(1):1-5. PMID: 2892771

[17] Jensen LS, Krarup N. Propranolol in prevention of rebleeding from oesophageal varices during the course of endoscopic sclerotherapy. Scand J Gastroenterol 1989;24(3):339-345. doi: 10.3109/00365528909093057. PMID: 2660250

[18] Kim SG, Kim TY, Sohn JH, Um SH, Seo YS, Baik SK*, et al.* A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis. Am J Gastroenterol 2016;111(11):1582-1590. doi: 10.1038/ajg.2016.327. PMID: 27575713

[19] Kumar A, Jha SK, Sharma P, Dubey S, Tyagi P, Sharma BC*, et al.* Addition of propranolol and isosorbide mononitrate to endoscopic variceal ligation does not reduce variceal rebleeding incidence. Gastroenterology 2009;137(3):892-901, 901.e891. doi: 10.1053/j.gastro.2009.05.049. PMID: 19481079

[20] Kumar M, Kainth S, Choudhury A, Maiwall R, Mitra LG, Saluja V*, et al.* Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial. Hepatol Int 2019;13(6):800-813. doi: 10.1007/s12072-019-09986-9. PMID: 31541422

[21] Lebrec D, Poynard T, Bernuau J, Bercoff E, Nouel O, Capron JP*, et al.* A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology 1984;4(3):355-358. doi: 10.1002/hep.1840040301. PMID: 6373547

[22] Lo GH, Lai KH, Lee SD, Tsai YT, Lo KJ. Does propranolol maintain post-sclerotherapy variceal obliteration? A prospective randomized study. J Gastroenterol Hepatol 1993;8(4):358-362. doi: 10.1111/j.1440-1746.1993.tb01528.x. PMID: 8374092

[23] Lo GH, Lai KH, Cheng JS, Chen MH, Huang HC, Hsu PI*, et al.* Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial. Hepatology 2000;32(3):461-465. doi: 10.1053/jhep.2000.16236. PMID: 10960435

[24] Lo GH, Chen WC, Wang HM, Yu HC. Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding. J Gastroenterol Hepatol 2012;27(11):1681-1687. doi: 10.1111/j.1440-1746.2012.07244.x. PMID: 22849337.

[25] Merkel C, Marin R, Angeli P, Zanella P, Felder M, Bernardinello E*, et al.* A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 2004;127(2):476-484. doi: 10.1053/j.gastro.2004.05.004. PMID: 15300580

[26] Pascal JP, Cales P. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 1987;317(14):856-861. doi: 10.1056/nejm198710013171403. PMID: 3306385

[27] de la Peña J, Brullet E, Sanchez-Hernández E, Rivero M, Vergara M, Martin-Lorente JL*, et al.* Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology 2005;41(3):572-578. doi: 10.1002/hep.20584. PMID: 15726659

[28] Pérez-Ayuso RM, Piqué JM, Bosch J, Panés J, González A, Pérez R*, et al.* Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet 1991;337(8755):1431-1434. doi: 10.1016/0140-6736(91)93125-s. PMID: 1675316

[29] Pomier-Layrargues G, Villeneuve JP, Willems B, Huet PM, Marleau D. Systemic and hepatic hemodynamics after variceal hemorrhage: effects of propranolol and placebo. Gastroenterology 1987;93(6):1218-1224. doi: 10.1016/0016-5085(87)90247-2. PMID: 3315825

[30] Sarin SK, Mishra SR, Sharma P, Sharma BC, Kumar A. Early primary prophylaxis with beta-blockers does not prevent the growth of small esophageal varices in cirrhosis: a randomized controlled trial. Hepatol Int 2013;7(1):248-256. doi: 10.1007/s12072-012-9353-8. PMID: 26201639

[31] The PROVA Study Group. Prophylaxis of first hemorrhage from esophageal varices by sclerotherapy, propranolol or both in cirrhotic patients: a randomized multicenter trial. The PROVA Study Group. Hepatology 1991;14(6):1016-1024. PMID: 1959848

[32] Villanueva C, Albillos A, Genescà J, Garcia-Pagan JC, Calleja JL, Aracil C*, et al.* β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2019;393(10181):1597-1608. doi: 10.1016/s0140-6736(18)31875-0. PMID: 30910320

[33] Villeneuve JP, Pomier-Layrargues G, Infante-Rivard C, Willems B, Huet PM, Marleau D*, et al.* Propranolol for the prevention of recurrent variceal hemorrhage: a controlled trial. Hepatology 1986;6(6):1239-1243. doi: 10.1002/hep.1840060602. PMID: 3539741